Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

TOKYO -- Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection of malignant pancreatic tumor, which was presented at the ASCO® Breakthrough meeting in Yokohama, Japan. IgA and CD209, markers of immunity enhanced while CA19-9, the marker of pancreatic cancer and CD44, that of cancer recurrence and severity, significantly reduced in patients who had Nichi BRITE, compared to the control group in the study by gastro-enterology surgeons and nutritional support team of Chikamori Hospital, Kochi, Japan. Importantly, the mean survival improved after Nichi BRITE administration. Read More

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.